Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.82 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | PDE2A | O00408 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30303132 | 1.00 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2PDE2A | |
| SCHEMBL20724628 | 1.00 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2PDE2A | |
| SCHEMBL23760829 | 1.00 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2PDE2A | |
| SCHEMBL8971384 | 1.00 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2PDE2A | |
| SCHEMBL6758941 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A | |
| SCHEMBL4803033 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A | |
| SCHEMBL14853634 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A | |
| SCHEMBL14928752 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A | |
| SCHEMBL18464461 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A | |
| SCHEMBL5879766 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20180009836-A1 | BETA-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINENUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS | Atea Pharmaceuticals, Inc. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009836-A1 | BETA-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINENUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS | MTAP, NSUN2, TPMT | ADORA3 93/4885ADORA1 116/4885PGK1 3779/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ADORA3 105/4885ADORA1 132/4885PGK1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.